Related Experiment Videos
Parent-to-child transplantation with cyclosporine immunosuppression
B D Kahan1, S Conley, R Portman
1Department of Surgery, University of Texas Medical School, Houston 77030.
Insights
Pediatric patients require higher doses of cyclosporine (immunosuppressive agent) due to rapid drug clearance, unlike adults. This adjustment is crucial for improving transplant outcomes in children.
Area of Science:
- Immunology
- Pharmacology
- Pediatric Medicine
Background:
- Cyclosporine, an immunosuppressive agent, has improved adult haploidentical transplantation outcomes.
- Its effectiveness in parent-to-child transplantation is less pronounced, with higher rates of allograft loss and rejection in pediatric recipients.
Purpose of the Study:
- To investigate the reasons for reduced efficacy of cyclosporine in pediatric transplant recipients compared to adults.
- To determine optimal dosing strategies for cyclosporine in children undergoing transplantation.
Main Methods:
- Comparative analysis of cyclosporine pharmacokinetics in pediatric and adult transplant recipients.
- Measurement of drug clearance, serum concentration-time curves, and trough serum levels using radioimmunoassay.
Main Results:
- Pediatric patients exhibit significantly faster cyclosporine clearance (39.6 mL/min/kg) than adults (12.3 mL/min/kg).
- This rapid clearance leads to a reduced area under the serum concentration curve and trough levels below the therapeutic threshold in children.
- Evidence of nephrotoxicity was lower in pediatric recipients.
Conclusions:
- The reduced efficacy of cyclosporine in pediatric transplant recipients is likely due to rapid drug clearance, not immune resistance.
- Higher doses and increased frequency of cyclosporine administration are necessary for pediatric patients compared to adults to achieve therapeutic levels.
Abstract:
The use of cyclosporine, a fungal endecapeptide immunosuppressive agent, has greatly improved the outcome of haploidentical transplantation in adults, but less impressively improved the result of parent to child transplantation. The incidence of allograft loss and treated rejection episodes was much greater in pediatric than in adult recipients, and the evidences of nephrotoxicity lessened. Although resistance of the child's immune system to the effects of the drug cannot be excluded, it appears more likely that this relates to the rapid clearance of the agent in the pediatric age group (39.6 mL/min/kg) versus in adults (12.3 mL/min/kg), thereby reducing the area under the serum concentration curve from 765 +/- 593 to 386 +/- 277 ng/mL/hr per mg/kg (mean +/- SD). This effect caused trough serum levels measured by radioimmunoassay to be below the putative threshold. These findings demonstrate the need for higher cyclosporine doses and frequency in pediatric compared with adult patients.